TN2009000446A1 - P70 s6 kinase inhibitors - Google Patents

P70 s6 kinase inhibitors

Info

Publication number
TN2009000446A1
TN2009000446A1 TNP2009000446A TN2009000446A TN2009000446A1 TN 2009000446 A1 TN2009000446 A1 TN 2009000446A1 TN P2009000446 A TNP2009000446 A TN P2009000446A TN 2009000446 A TN2009000446 A TN 2009000446A TN 2009000446 A1 TN2009000446 A1 TN 2009000446A1
Authority
TN
Tunisia
Prior art keywords
kinase inhibitors
formula
methods
provides
present
Prior art date
Application number
TNP2009000446A
Other languages
English (en)
Inventor
Robert Dean Dally
Jianping Huang
Sajan Joseph
Timothy Alan Shepherd
Christian L Holst
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TN2009000446A1 publication Critical patent/TN2009000446A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TNP2009000446A 2007-05-11 2009-10-28 P70 s6 kinase inhibitors TN2009000446A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11
PCT/US2008/062143 WO2008140947A1 (fr) 2007-05-11 2008-05-01 Inhibiteurs de la p70 s6 kinase

Publications (1)

Publication Number Publication Date
TN2009000446A1 true TN2009000446A1 (en) 2011-03-31

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000446A TN2009000446A1 (en) 2007-05-11 2009-10-28 P70 s6 kinase inhibitors

Country Status (34)

Country Link
US (2) US8093383B2 (fr)
EP (1) EP2148880B1 (fr)
JP (1) JP5503532B2 (fr)
KR (1) KR101088219B1 (fr)
CN (1) CN101679439B (fr)
AR (1) AR066344A1 (fr)
AU (1) AU2008251692B2 (fr)
BR (1) BRPI0811212A2 (fr)
CA (1) CA2687265C (fr)
CL (1) CL2008001230A1 (fr)
CO (1) CO6241109A2 (fr)
CR (1) CR11106A (fr)
DK (1) DK2148880T3 (fr)
DO (1) DOP2009000257A (fr)
EA (1) EA016445B1 (fr)
EC (1) ECSP099721A (fr)
ES (1) ES2483726T3 (fr)
GT (1) GT200900292A (fr)
HK (1) HK1140767A1 (fr)
HR (1) HRP20140611T1 (fr)
IL (1) IL201564A (fr)
MA (1) MA31433B1 (fr)
MX (1) MX2009012075A (fr)
MY (1) MY154898A (fr)
NZ (1) NZ580423A (fr)
PE (1) PE20090887A1 (fr)
PL (1) PL2148880T3 (fr)
PT (1) PT2148880E (fr)
RS (1) RS53451B (fr)
SI (1) SI2148880T1 (fr)
TN (1) TN2009000446A1 (fr)
TW (1) TWI423805B (fr)
UA (1) UA99284C2 (fr)
WO (1) WO2008140947A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
WO2010019762A1 (fr) * 2008-08-13 2010-02-18 Jenrin Discovery Composés de purine en tant que bloqueurs de récepteur aux cannabinoïdes
US8334293B2 (en) 2008-11-11 2012-12-18 Eli Lilly And Company P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
KR20110075014A (ko) * 2008-11-11 2011-07-05 일라이 릴리 앤드 캄파니 Ｐ70 ｓ6 키나제 억제제 및 ｍｔｏｒ 억제제 조합 요법
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
BRPI1008325A2 (pt) 2009-02-11 2020-08-25 Merck Patent Gmbh carboxamidas azaeterocíclicas de amino
US9023847B2 (en) 2009-08-07 2015-05-05 Merck Patent Gmbh Azaheterocyclic compounds
EP2491032B1 (fr) 2009-10-23 2014-04-16 Eli Lilly and Company Inhibiteurs d'akt
EP2992878A1 (fr) 2010-02-03 2016-03-09 Signal Pharmaceuticals, LLC Identification d'une mutation lkb1 comme biomarqueur prédictif de la sensibilité aux inhibiteurs de la kinase tor
KR101945061B1 (ko) 2010-07-29 2019-02-01 메르크 파텐트 게엠베하 시클릭 아민 아자헤테로시클릭 카르복사미드
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
CN103228649B (zh) 2010-11-24 2015-11-25 默克专利股份公司 喹唑啉甲酰胺氮杂环丁烷
ES2644536T3 (es) * 2011-09-12 2017-11-29 Merck Patent Gmbh Imidazol-aminas novedosas como moduladores de la actividad cinasa
RS56486B1 (sr) 2011-09-12 2018-01-31 Merck Patent Gmbh Aminopirimidin derivati za upotrebu kao modulatori aktivnosti kinaza
WO2014039714A2 (fr) * 2012-09-06 2014-03-13 Plexxikon Inc. Composés et procédés pour la modulation des kinases, et leurs indications
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
WO2014078634A1 (fr) * 2012-11-16 2014-05-22 Merck Patent Gmbh Nouveaux dérivés imidazol-pipéridinyle en tant que modulateurs de l'activité kinase
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
CA2887539C (fr) 2012-11-29 2021-10-26 Merck Patent Gmbh Derives carboxamide d'azaquinazoline
AR095202A1 (es) 2013-03-11 2015-09-30 Merck Patent Gmbh Heterociclos como moduladores de la actividad quinasa
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
KR102271344B1 (ko) 2013-04-17 2021-07-01 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
CA2908742C (fr) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Polytherapie comprenant un inhibiteur de la kinase tor et un analogue de la cytidine pour le traitement du cancer
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
AU2014254058B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
EP2986319A1 (fr) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Thérapie combinée comprenant un inhibiteur de la kinase tor et du n-(3-(5-fluoro-2-(4-(2-méthoxyéthoxy)phénylamino)pyrimidin-4-ylamino)phényl)acrylamide pour le traitement d'un cancer
CN105339009B (zh) 2013-04-17 2018-08-28 西格诺药品有限公司 用于治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
WO2014193912A1 (fr) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Compositions pharmaceutiques de 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-l-((trans)-4-méthoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(lh)-one, forme solide de celle-ci et procédés pour les utiliser
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
NZ725361A (en) 2014-04-03 2022-09-30 Merck Patent Gmbh Combinations of cancer therapeutics
WO2015160880A1 (fr) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016040078A1 (fr) * 2014-09-10 2016-03-17 Eli Lilly And Company Composés de phénylimidazolylpipéridyle substitués utilisés en tant qu'inhibiteurs de p70s6k1
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
US20240024324A1 (en) 2020-11-16 2024-01-25 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1750727A2 (fr) * 2004-04-23 2007-02-14 Exelixis, Inc. Modulateurs des proteines kinases et leurs methodes d'utilisation
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006071819A1 (fr) 2004-12-28 2006-07-06 Exelixis, Inc. Composes piperazine ou [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine utilises en tant que modulateurs des serine-theoronine kinases (p70s6k, atk1 et atk2) pour le traitement de maladies immunologiques, inflammatoires et proliferantes
EP1907383A1 (fr) 2005-06-30 2008-04-09 Prosidion Limited Agonistes du gpcr
WO2007125310A2 (fr) 2006-04-25 2007-11-08 Astex Therapeutics Limited Combinaisons pharmaceutiques
EP3421471B1 (fr) 2006-04-25 2021-05-26 Astex Therapeutics Limited Dérivés de purine et de déazapurine comme composés pharmaceutiques
WO2008012635A2 (fr) 2006-07-26 2008-01-31 Pfizer Products Inc. Dérivés d'amines utiles en tant qu'agents anticancéreux
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
KR101088219B1 (ko) 2011-11-30
AR066344A1 (es) 2009-08-12
ES2483726T3 (es) 2014-08-07
EA016445B1 (ru) 2012-05-30
SI2148880T1 (sl) 2014-07-31
JP2010526814A (ja) 2010-08-05
CL2008001230A1 (es) 2009-05-22
IL201564A (en) 2014-08-31
TWI423805B (zh) 2014-01-21
AU2008251692B2 (en) 2012-10-11
AU2008251692A1 (en) 2008-11-20
US8093383B2 (en) 2012-01-10
CN101679439B (zh) 2013-09-11
CA2687265A1 (fr) 2008-11-20
IL201564A0 (en) 2010-05-31
KR20100005710A (ko) 2010-01-15
HRP20140611T1 (hr) 2014-08-15
HK1140767A1 (en) 2010-10-22
DK2148880T3 (da) 2014-06-16
EP2148880A1 (fr) 2010-02-03
US20120071490A1 (en) 2012-03-22
PT2148880E (pt) 2014-08-28
EP2148880B1 (fr) 2014-05-28
JP5503532B2 (ja) 2014-05-28
CA2687265C (fr) 2012-12-04
MY154898A (en) 2015-08-28
MA31433B1 (fr) 2010-06-01
MX2009012075A (es) 2009-11-19
DOP2009000257A (es) 2010-03-31
UA99284C2 (ru) 2012-08-10
US20090163714A1 (en) 2009-06-25
CR11106A (es) 2010-04-12
WO2008140947A1 (fr) 2008-11-20
CO6241109A2 (es) 2011-01-20
NZ580423A (en) 2012-02-24
PL2148880T3 (pl) 2014-10-31
BRPI0811212A2 (pt) 2014-10-29
CN101679439A (zh) 2010-03-24
PE20090887A1 (es) 2009-07-13
RS53451B (en) 2014-12-31
ECSP099721A (es) 2009-12-28
TW200848053A (en) 2008-12-16
EA200971051A1 (ru) 2010-06-30
GT200900292A (es) 2011-06-24

Similar Documents

Publication Publication Date Title
MY154898A (en) P70 s6 kinase inhibitors
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
TW201713640A (en) Bruton's tyrosine kinase inhibitors
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MY148634A (en) Pyridazinone derivatives
MY181898A (en) Heterocyclic compounds and uses thereof
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
MX2012004780A (es) Inhibidores de akt.
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
MY153915A (en) Organic compounds
WO2011032169A3 (fr) Compositions et formulations pharmaceutiques comprenant des inhibiteurs du domaine d'homologie à la pleckstrine et leurs méthodes d'utilisation
SE0301372D0 (sv) Novel compounds
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
WO2009024611A3 (fr) 4-benzylaminoquinoléines, compositions pharmaceutiques les contenant, et leur utilisation en thérapie
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2008001538A (es) Aril piridinas y metodos para su uso.
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
RS20090036A (en) Pyrazole derivatives as cytochrom p450 inhibitors
PL2079446T3 (pl) Preparat paliperidonu o przedłużonym uwalnianiu
TNSN08191A1 (en) Kinase inhibitors
UA85505C2 (en) Kinase inhibitors
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-